ATR

AptarGroup, Inc.

Fundamental data last updated:September 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

 


Analyze ATR on TradingView

VALUATION

P/E

19.19

Market Cap ($M USD)

$7.39B

Forward P/E

16.37

PEG

0.95

PRICE TO SALES

1.91

PRICE TO BOOK

2.82

EV / EBITDA

10.70

5-Year Average P/E

Free Cash Flow Yield

4.40%

DCF Value

$183.46

Graham Number

$74.68

Price to FCF

22.72

EV to FCF

26.36

Earnings Yield

5.21%

FCF Yield

4.40%

DIVIDEND

Yield

1.63%

Annual Payout

$1.89

Payout Ratio

31.50%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$6.04

Next Year EPS Growth Estimate

$7.08

Next Year Revenue Growth Estimate

$4.42B

Return on Equity (ROE)

14.33%

FREE CASH FLOW

Operating Margin

13.02%

Debt-to-Equity

0.57

Piotroski F-Score

6

Altman Z-Score

3.81

Return on Invested Capital (ROIC)

12.50%

Current Ratio

1.66

Quick Ratio

1.14

Net Debt to EBITDA

1.48

Interest Coverage

8.65

Gross Profit margin

28.99%

FCF PER SHARE

$5.08

REVENUE PER SHARE

$60.46

Analyze ATR on TradingView

Gainseekers Quantitative Analysis

Summary

ATR AptarGroup, Inc. appears to be a compelling opportunity for value investors. Recent pricing indicated it traded below its DCF Value, suggesting potential undervaluation. The Forward P/E of 17.10 and an Earnings Yield of 4.99% reflect a reasonable valuation for a company with a solid growth trajectory. The Altman Z-score of 3.90 indicates financial stability, reducing the risk of distress. Overall, the market seems to be underestimating its intrinsic value, presenting a potential buying opportunity.

AI Exposure / Tech Reliance

Operating in the Medical - Instruments & Supplies industry, ATR is well-positioned to leverage AI and modern tech advancements. The healthcare sector's ongoing digital transformation offers opportunities for innovation and efficiency improvements. ATR's focus on medical supplies aligns with these technological shifts, potentially enhancing its competitive edge.

The Bull Case

For the discerning GARP investor, ATR's strengths are evident. With a robust ROIC of 12.50%, the company demonstrates efficient capital allocation. The Piotroski F-Score of 6 suggests solid financial health, while a Free Cash Flow Yield of 4.22% indicates strong cash generation. Its operating margin of 13.02% underscores pricing power, making it an attractive proposition for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, ATR faces notable challenges. The Price/Book ratio of 2.95 and Price/Sales of 1.99 suggest it may not be a bargain on a relative basis. The EV to FCF ratio of 27.37 raises concerns about cash flow valuation. Additionally, trading significantly below its 50-Day and 200-Day SMAs indicates potential technical weakness, which could deter momentum investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$188.00

Institutional Ownership %

1-Year Beta

0.42

Insider Buying % (6 Mo)

Distance to 52-Week High

41.80%

Distance to 52-Week Low

10.89%

EARNINGS SURPRISE %

3.48%

50-DAY SMA

$123.07

200-DAY SMA

$127.71

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.